When Osimertinib Stops Working: — Resistance and What Comes Next

C797S sits in the same part of the EGFR gene that osimertinib targets, making third-generation EGFR inhibitors ineffective against it. Whether earlier-generation EGFR inhibitors are useful depends on whether the original sensitising mutation is present in the same cancer cell as C797S or in different cells — a distinction your oncologist will explain using the full molecular report. Combinations that address both mutations are under active investigation in clinical trials, and your team will review whether an eligible trial exists for your specific profile.

MET amplification activates a growth pathway that runs parallel to EGFR and is not blocked by osimertinib at standard doses. MET inhibitors, used alongside continued or modified EGFR blockade, are being studied in this setting and have regulatory approval in some countries. The degree of amplification, measured on the biopsy result, can influence the decision. Ask your oncologist whether a MET inhibitor combination, chemotherapy, or a clinical trial is the recommended approach given your specific result.

A proportion of patients have resistance that current testing does not fully explain. This is not unusual and does not mean the testing was inadequate. In this situation, the decision between chemotherapy and other approaches is made on clinical grounds — how quickly the cancer is progressing, where it has spread, and your overall fitness. NCCN guidance acknowledges that the next-line decision in this group is less standardised, which is one reason why reviewing the case at a multidisciplinary tumour board is valuable before committing to a regimen.

Chemotherapy has not been made ineffective by prior osimertinib. EGFR-mutant tumours respond to platinum-based chemotherapy regimens, and this is the treatment pathway a large proportion of patients eventually follow. Amivantamab combined with carboplatin and pemetrexed has data from large randomised trials in the post-osimertinib setting and has been reviewed by ESMO and approved in several regulatory jurisdictions as a specific option at this point in treatment.

Progression after osimertinib is the moment when a clinical trial is most likely to offer access to a genuinely new mechanism of action. Several trials are designed specifically for the resistance patterns that develop after osimertinib, including for C797S, MET amplification, and other alterations. Trial eligibility depends on your specific mutation profile, organ function, and prior treatment history. Your oncologist can search available trials, or you can ask the team to look up your specific resistance mutation on ClinicalTrials.gov.

In a small number of patients, re-challenge with osimertinib after a break has occasionally produced a response, but this is not a standard recommendation and the evidence is limited to case series rather than randomised trial data. The setting where it may come up is where a patient stopped osimertinib for a reason other than resistance and then progressed — which is a different situation from developed acquired resistance. Your oncologist will be direct about whether this is a realistic consideration for your specific case and what the realistic expectations are.